Referring to the CATIE trial, the findings suggested perphenazine was not significantly different in effectiveness, Quality Adjusted Life Years (QALY), or other quality of life measurements compared to the 2nd generation antipsychotics (olanzapine, quetiapine, risperidone, and ziprasidone) but perphenazine was considered more cost effective. Is this still true? Please choose the correct answer below. Referring to the CATIE trial, the findings suggested perphenazine was not significantly different in effectiveness, Quality Adjusted Life Years (QALY), or other quality of life measurements compared to the 2nd generation antipsychotics (olanzapine, quetiapine, risperidone, and ziprasidone) but perphenazine was considered more cost effective. Is this still true? Please choose the correct answer below. No, due to the cost of 2nd generation antipsychotics being reduced because of low cost generic alternatives. Yes, the 2nd generation antipsychotics are only available in name brand form which leads to increased costs. Yes, cost of monitoring perphenazine has increased significantly. No, perphenazine is no longer on the market